The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era

References

• Lee C K. Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am 2006; 20: 471–503
   PubMed Web of Science ®Google Scholar
• Nieder C, Licht T, Andratschke N, Peschel C, Molls M. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev 2003; 29: 11–19
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 2003; 42: 605–619
   PubMed Web of Science ®Google Scholar
• Cox J D, Ha C S, Lee H K, Dabaja B S, Wilder R B. Uncertainties in contemporary treatment of aggressive lymphomas. Rays 2003; 28: 289–292
   PubMedGoogle Scholar
• Miller T P, Dahlberg S, Cassady J R, Adelstein D J, Spier C M, Grogan T M, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–26
   PubMed Web of Science ®Google Scholar
• Horning S J, Weller E, Kim K, Earle J D, O'Connell M J, Habermann T M, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032–3038
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, Molina T J, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197–1205
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N, Ganem G, Molina T J, Thieblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787–792
   PubMed Web of Science ®Google Scholar
• Aviles A, Delgado S, Ruiz H, de la Torre A, Guzman R, Talavera A. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol 1996; 32B: 19–23
   PubMed Web of Science ®Google Scholar
• Aviles A, Fernandezb R, Perez F, Nambo M J, Neri N, Talavera A, et al. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 2004; 45: 1385–1389
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Delgado S, Perez F, Nambo M J, Cleto S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol 2005; 22: 383–387
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087–2106
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-hodgkin's lymphoma pathologic classification project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Lossos I S, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005; 4: 7–14
   PubMedGoogle Scholar
• Tsang R W, Gospodarowicz M K. Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol 2001; 80(Suppl 3)B66–B72
   PubMed Web of Science ®Google Scholar
• Berrios-Rivera J P, Fang S, Cabanillas M E, Cabanillas F, Lu H, Du X L. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol 2007; 30: 163–171
   PubMed Web of Science ®Google Scholar
• Longo D L. Combined modality therapy for localized aggressive lymphoma: enough or too much?. J Clin Oncol 1989; 7: 1179–1181
   PubMed Web of Science ®Google Scholar
• Miller T P, Spier C M, Rimsza L. Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease. Semin Hematol 2006; 43: 207–212
   PubMed Web of Science ®Google Scholar
• Miller T P. The limits of limited stage lymphoma. J Clin Oncol 2004; 22: 2982–2984
   PubMed Web of Science ®Google Scholar
• Ng A K, Mauch P M. Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol 2007; 25: 757–759
   PubMed Web of Science ®Google Scholar
• Friedberg J W. Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol 2006; 7: 357–359
   Google Scholar
• Shenkier T N, Voss N, Fairey R, Gascoyne R D, Hoskins P, Klasa R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002; 20: 197–204
   PubMed Web of Science ®Google Scholar
• Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 720–725
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523
   PubMed Web of Science ®Google Scholar
• Ng A P, Wirth A, Seymour J F, Lee M, Hogg A, Januszewicz H, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007; 48: 596–600
   PubMed Web of Science ®Google Scholar
• Sutcliffe S B, Gospodarowicz M K, Brown T C, Chua T, Bean H A, Bush R S, et al. Role of radiation therapy in localized non-Hodgkin's Lymphoma. Radiother Oncol 1985; 4: 211–223
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• van der Maazen R W, Noordijk E M, Thomas J, Raemaekers J M, Meerwaldt J H. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol 1998; 49: 1–7
   PubMed Web of Science ®Google Scholar
• Miller T P, Jones S E. Chemotherapy of localised histiocytic lymphoma. Lancet 1979; 1: 358–360
   PubMed Web of Science ®Google Scholar
• Connors J M, Klimo P, Fairey R N, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107: 25–30
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Bodey G P, Freireich E J. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980; 46: 2356–2359
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. Hematol Oncol 1985; 3: 25–31
   PubMed Web of Science ®Google Scholar
• Jones S E, Miller T P, Connors J M. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989; 7: 1186–1191
   PubMed Web of Science ®Google Scholar
• Miller T, LeBlanc M, Spier C, Chase E, Fischer R. CHOP alone compared to CHOP plus radiotherapy for early-stage aggressive non-Hodgkin lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98: 724a
   Google Scholar
• Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284–4289
   PubMed Web of Science ®Google Scholar
• Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, et al. Long-term outcome of localized high-.grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study. Haematologica 2005; 90: 802–809
   PubMed Web of Science ®Google Scholar
• Shikama N, Oguchi M, Isobe K, Nakamura K, Tamaki Y, Hasegawa M, et al. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: 217–222
   PubMed Web of Science ®Google Scholar
• Miller T, Unger J, Spier C, Stea B. Effect of adding Rituximab to three cycles of CHOP plus involved field radiotherapy for limited stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 2004; 104: 48a–49a
   Web of Science ®Google Scholar
• Longo D L, Glatstein E, Duffey P L, Ihde D C, Hubbard S M, Fisher R I, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 7: 1295–1302
   PubMed Web of Science ®Google Scholar
• Eich H T, Staar S, Gossmann A, Hansemann K, Skripnitchenko R, Kocher M, et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004; 58: 1121–1127
   PubMed Web of Science ®Google Scholar
• Aleman B M, Girinsky T, van der Maazen R W, Strijk S, Meijnders P, Bortolus R, et al. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys 2005; 63: 1184–1190
   PubMed Web of Science ®Google Scholar
• Ganem G, Reyes F, Lepage E, Gaillerd I, Munck J, Morel P, et al. Three CHOP followed by radiotherapy versus a more intensive Chemotherapy alone in low risk localised aggressive non-Hodgkin's lymphoma: preliminary results of the GELA LNH 93-1 study. Int journal of radiat oncol Biol Phys 2001; 51: 67
   Google Scholar
• Gospodarowicz M K, Sutcliffe S B. The extranodal lymphomas. Semin Radiat Oncol 1995; 5: 281–300
   PubMedGoogle Scholar
• Newton R, Ferlay J, Beral V, Devesa S S. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer 1997; 72: 923–930
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Colomo L, Jimenez M, Bosch F, Villamor N, Arenillas L, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797–2804
   PubMed Web of Science ®Google Scholar
• Ferreri A J, Batchelor T, Zucca E, Cavalli F, Armitage J. International Collaborative Group against primary CNS lymphomas. J Clin Oncol 2003; 21: 1649–1650
   PubMed Web of Science ®Google Scholar
• Gavrilovic I T, Hormigo A, Yahalom J, DeAngelis L M, Abrey L E. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570–4574
   PubMed Web of Science ®Google Scholar
• Batchelor T, Loeffler J S. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281–1288
   PubMed Web of Science ®Google Scholar
• Bessell E M, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231–236
   PubMed Web of Science ®Google Scholar
• Fisher B, Seiferheld W, Schultz C, DeAngelis L, Nelson D, Schold S C, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 2005; 74: 201–205
   PubMed Web of Science ®Google Scholar
• Yahalom J, Shah G D, Lai R K, Correa D D, DeAngelis L M, Abrey L. Reduced-dose whole brain radiotherapy following complete response to immuno-chemotherapy in patients with primary CNS lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: S84
   Web of Science ®Google Scholar
• Zucca E, Conconi A, Mughal T I, Sarris A H, Seymour J F, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20–27
   PubMed Web of Science ®Google Scholar
• Vitolo U, Zucca E, Martelli M, Chiapella A, Baldi I, Balzarrotti M, et al. Primary diffuse large B-cell lymphoma of the testis: a prospective study of rituximab (R)-CHOP with CNS and contralateral testis prohylaxis. Results of IELSG 10 study. Blood 2006; 108: 65a
   Web of Science ®Google Scholar
• Ryan G, Martinelli G, Yuen K, Seymour J. Primary non-Hodgkin's lymphoma of the breast: first report of the multicentre retrospective study of the International Extranodal Lymphoma Study Group (IELSG-15). J Clin Oncol 2005; 23: 6575
   Google Scholar
• Wong W W, Schild S E, Halyard M Y, Schomberg P J. Primary non-Hodgkin lymphoma of the breast: the Mayo clinic experience. J Surg Oncol 2002; 80: 19–25, discussion 26
   PubMed Web of Science ®Google Scholar
• Ganjoo K, Advani R, Mariappan M R, McMillan A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer 2007; 110: 25–30
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Mian M, Rossi A, Oldani E. Primary extranodal diffuse large B-cell lymphomas arising in distinct sites of head and neck have different clinical characteristics and outcome. Haematologica 2007; 92(S1), abstract 862.
   Google Scholar
• Christie D, Gracia E, Gospodarowicz M, Martinelli G. Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): a survey of 499 cases by the International Extranodal Lymphoma Study Group. Haematologica 2007; 92(S1), abstract 717
   Google Scholar
• Park Y H, Lee S H, Kim W S, Bang S M, Ryoo B Y, Yang S H, et al. CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. Leuk Lymphoma 2006; 47: 1253–1259
   PubMed Web of Science ®Google Scholar
• O H D, Choi I S, Kim J H, Rhu M H, Kim T Y, Heo D S, et al. Management of gastric lymphoma with chemotherapy alone. Leuk Lymphoma 2005; 46: 1329–1335
   PubMed Web of Science ®Google Scholar
• Wohrer S, Troch M, Raderer M. Treatment of localized primary gastric lymphoma. J Clin Oncol 2006; 24: 2682, author reply 2682 – 2683
   PubMed Web of Science ®Google Scholar
• Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 2004; 15: 1086–1090
   PubMed Web of Science ®Google Scholar
• Ishikura S, Tobinai K, Ohtsu A, Nakamura S, Yoshino T, Oda I, et al. Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 2005; 96: 349–352
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855–1864
   PubMed Web of Science ®Google Scholar
• Savage K J. Primary mediastinal large B-cell lymphoma. Oncologist 2006; 11: 488–495
   PubMed Web of Science ®Google Scholar
• Savage K J, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne R D, Connors J M. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123–130
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372–376
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999; 94: 3289–3293
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Bertini M, Gianni A M, Devizzi L, Federico M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258–1264
   PubMed Web of Science ®Google Scholar
• Ott G, Rosenwald A. Extranodal diffuse large B-cell lymphoma—an organotypic disease?. Pathologe in press
   Web of Science ®Google Scholar
• Fisher R I, DeVita V T, Jr, Johnson B L, Simon R, Young R C. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977; 63: 177–182
   PubMed Web of Science ®Google Scholar
• Jagannath S, Velasquez W S, Tucker S L, Fuller L M, McLaughlin P W, Manning J T, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4: 859–865
   PubMed Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Vose J M, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’. Ann Oncol 1992; 3: 711–717
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Reverter J C, Cervantes F, Escoda L, Tassies D, et al. Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma 1993; 10: 101–109
   PubMed Web of Science ®Google Scholar
• Pfreunschuh. Prognostic significance of maximal tumor size (MTS) in young patients with good-prognosis diffuse large B-cell lymphoma (DLBCL) treated with CHOP-like chemotherapy with and without rituximab: Analysis of the Mabthera International Trial Group (MInT) study. J Clin Oncol 2007; 25: 454s
   PubMed Web of Science ®Google Scholar
• Shipp M A, Klatt M M, Yeap B, Jochelson M S, Mauch P M, Rosenthal D S, et al. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol 1989; 7: 613–618
   PubMed Web of Science ®Google Scholar
• Morgan S, Wirth A, Wolf M, Stone J, Reynolds J, Prince H. Patterns of Failure in ALLG Intermediate Grade Non-Hodgkin's Lymphoma (intNHL) Studies 2004. Proceedings of the Haematology Society of Australia and New Zealand 2004; abstract 60: 109
   Google Scholar
• Rube C, Nguyen T P, Kloss M, Loeffler M, Trumper L, Pfreunschuh M. Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Hematol 2001; 80(Suppl 3)B84–B85
   PubMed Web of Science ®Google Scholar
• Schlembach P J, Wilder R B, Tucker S L, Ha C S, Rodriguez M A, Hess M A, et al. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 2000; 48: 1107–1110
   PubMed Web of Science ®Google Scholar
• Ferreri A J, Dell'Oro S, Reni M, Ceresoli G L, Cozzarini C, Ponzoni M, et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology 2000; 58: 219–226
   PubMed Web of Science ®Google Scholar
• Wilder R B, Rodriguez M A, Tucker S L, Ha C S, Hess M A, Cabanillas F F, et al. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 2001; 50: 743–749
   PubMed Web of Science ®Google Scholar
• Moser E C, Kluin-Nelemans H C, Carde P, Meerwaldt J H, Tirelli U, Aleman B M, et al. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: 1168–1177
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Zijlstra J M, Lindauer-van der Werf G, Hoekstra O S, Hooft L, Riphagen I I, Huijgens P C. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522–529
   PubMed Web of Science ®Google Scholar
• Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007; 48: 270–282
   PubMed Web of Science ®Google Scholar
• Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
   PubMed Web of Science ®Google Scholar
• Kahn S T, Flowers C, Lechowicz M J, Hollenbach K, Johnstone P A. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 961–965
   PubMed Web of Science ®Google Scholar
• Aref A, Mohammad R, Yudelev M, Choudhuri R, Strowbridge A, Orton C, et al. Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines. Radiat Oncol Investig 1999; 7: 158–162
   PubMedGoogle Scholar
• Aref A, Narayan S, Tekyi-Mensah S, Varterasian M, Dan M, Eilender D, et al. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma. Radiat Oncol Investig 1999; 7: 186–191
   PubMedGoogle Scholar
• Kamath S S, Marcus R B, Jr, Lynch J W, Mendenhall N P. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 563–568
   PubMed Web of Science ®Google Scholar
• Fuller L M, Krasin M J, Velasquez W S, Allen P K, McLaughlin P, Rodriguez M A, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys 1995; 31: 3–11
   PubMed Web of Science ®Google Scholar
• Moskowitz C. Phase II Trial: dose dense CHOP followed by risk adapted consolidation with either ICE or ICE/ASCT: based on the results of biopsy confirmed abnormal restaging interim PET scan. Blood 2006; 106: 582a
   Google Scholar
• Ng A K, Mauch P M. Late complications of therapy of Hodgkin's disease: prevention and management. Curr Hematol Rep 2004; 3: 27–33
   PubMedGoogle Scholar
• Franklin J, Pluetschow A, Paus M, Specht L, Anselmo A P, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749–1760
   PubMed Web of Science ®Google Scholar
• Moser E C, Noordijk E M, Carde P, Tirelli U, Baars J W, Thomas J, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 2005; 6: 122–130
   PubMedGoogle Scholar
• Moser E C, Noordijk E M, van Leeuwen F E, Baars J W, Thomas J, Carde P, et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica 2006; 91: 1481–1488
   PubMed Web of Science ®Google Scholar
• Moser E C, Noordijk E M, van Leeuwen F E, le Cessie S, Baars J W, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107: 2912–2919
   PubMed Web of Science ®Google Scholar
• Tward J D, Wendland M M, Shrieve D C, Szabo A, Gaffney D K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107: 108–115
   PubMed Web of Science ®Google Scholar
• Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270–277
   PubMed Web of Science ®Google Scholar
• Koh E S, Tran T H, Heydarian M, Sachs R K, Tsang R W, Brenner D J, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007; 2: 13
   PubMed Web of Science ®Google Scholar
• Travis L B, Hill D A, Dores G M, Gospodarowicz M, van Leeuwen F E, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama 2003; 290: 465–475
   PubMed Web of Science ®Google Scholar
• Friedman D L, Constine L S. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006; 4: 249–257
   PubMedGoogle Scholar
• Das P, Ng A K, Earle C C, Mauch P M, Kuntz K M. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 2006; 17: 785–793
   PubMed Web of Science ®Google Scholar
• Apter S, Shemesh J, Raanani P, Portnoy O, Thaler M, Zissin R, et al. Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation. Coron Artery Dis 2006; 17: 145–151
   PubMed Web of Science ®Google Scholar
• Faulkner K, Law J. Mammographic breast cancer screening for women previously treated with high breast doses for diseases such as Hodgkin's. Radiat Prot Dosimetry 2005; 117: 330–333
   PubMed Web of Science ®Google Scholar
• Patel D A, Kochanski J, Suen A W, Fajardo L F, Hancock S L, Knox S J. Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer 2006; 106: 718–725
   PubMed Web of Science ®Google Scholar
• Amadori D, Ronconi S. Secondary lung tumors in hematological patients. Semin Respir Crit Care Med 2005; 26: 520–526
   PubMed Web of Science ®Google Scholar
• Koh E S, Sun A, Tran T H, Tsang R, Pintilie M, Hodgson D C, et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: 223–228
   PubMed Web of Science ®Google Scholar
• Jagsi R, Griffith K A, Koelling T, Roberts R, Pierce L J. Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer. J Clin Oncol 2006; 24: 2779–2785
   PubMed Web of Science ®Google Scholar
• Dorresteijn L D, Stewart F A, Boogerd W. Stroke as a late treatment effect of Hodgkin's disease. J Clin Oncol 2006; 24: 1480, author reply 1480 – 1481
   PubMed Web of Science ®Google Scholar
• Mantini G, Smaniotto D, Balducci M, Dinapoli N, Campitelli M, Corvari B, et al. Radiation-induced cardiovascular disease: impact of dose and volume. Rays 2005; 30: 157–168
   PubMedGoogle Scholar
• Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 2005; Suppl: 90–97
   Google Scholar
• Lee Y K, Cook G, Flower M A, Rowbottom C, Shahidi M, Sharma B, et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 2004; 73: 277–283
   PubMed Web of Science ®Google Scholar
• Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 62: 745–751
   PubMed Web of Science ®Google Scholar
• Nieder C, Schill S, Kneschaurek P, Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 2007; 82: 301–307
   PubMed Web of Science ®Google Scholar
• Goodman K A, Toner S, Hunt M, Wu E J, Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005; 62: 198–206
   PubMed Web of Science ®Google Scholar
• Beasley M, Driver D, Dobbs H J. Complications of radiotherapy: improving the therapeutic index. Cancer Imaging 2005; 5: 78–84
   PubMedGoogle Scholar
• Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 2006; 107: 2525–2534
   PubMed Web of Science ®Google Scholar
• Wilder R B, Tucker S L, Ha C S, Rodriguez M A, Hess M A, Cabanillas F F, et al. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001; 49: 17–22
   PubMed Web of Science ®Google Scholar
• Mirza M R, Brincker H, Specht L. The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 1992; 12: 217–229
   PubMed Web of Science ®Google Scholar
• Hoskin P, et al. Radiation dose in non-Hodgkin's lymphoma: preliminary results of a UK NCRN randomised trial. Ann Oncol 2005; 16(S5), abstract 59
   Google Scholar
• Isobe K, Kawakami H, Tamaru J, Yasuda S, Uno T, Aruga T, et al. Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: a prospective study. Leuk Lymphoma 2003; 44: 1535–1539
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Armitage J O. How I treat patients with diffuse large B-Cell lymphoma. Blood 2007
   Google Scholar
• Ferreri A J, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63: 257–268
   PubMed Web of Science ®Google Scholar
• Hamlin P A, Portlock C S, Straus D J, Noy A, Singer A, Horwitz S M, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130: 691–699
   PubMed Web of Science ®Google Scholar
• Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 2005; 6: 773–779
   PubMed Web of Science ®Google Scholar
• Martin W G, Ristow K M, Habermann T M, Colgan J P, Witzig T E, Ansell S M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614–7620
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Higgins C D, Smith P, Cunningham D, Hancock B W, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206–214
   PubMed Web of Science ®Google Scholar